stars 1 stars 2 stars 3

We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at

View Top Employees from FibroGen, Inc.
Ticker FGEN
Revenue $212 million
Funding $233.8 million
Employees 540 (540 on RocketReach)
Founded 1993
Address 409 Illinois St, San Francisco, California 94158, US
Phone (415) 978-1200
Fax (415) 978-1902
JavaScript, HTML, Twitter +42 more (view full list)
Category Biotechnology Research, Pharmaceuticals, Biopharma, Anemia, Healthcare, Biotechnology, Chronic Kidney Disease, Health Care, Cytoprotection, Science and Engineering, Fibrotic Disease, Therapeutics
Web Rank 7 Million
Keywords fibrogen, fibrogen news, san francisco biotech companies, fibergen, roxadustat
Competitors Akebia Therapeutics, Lexicon Pharmaceuticals, Inc., Light Chain Bioscience | Novimmune SA, Portola Pharmaceuticals, Reata Pharmaceuticals, Inc.
SIC 28, 283
NAICS 32541, 541, 5417, 325414, 3254, 325, 54171, 32, 54, 541711

FibroGen, Inc. Questions

The FibroGen, Inc. annual revenue was $212 million in 2023.

Tricia Stewart is the Chief People Officer of FibroGen, Inc..

540 people are employed at FibroGen, Inc..

FibroGen, Inc. is based in San Francisco, California.

The NAICS codes for FibroGen, Inc. are [32541, 541, 5417, 325414, 3254, 325, 54171, 32, 54, 541711].

The SIC codes for FibroGen, Inc. are [28, 283].

Top FibroGen, Inc. Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
G2Crowd Trusted
300K+ Plugin Users